Prevention Of Stroke In Nonvalvular Atrial Fibrillation
Key Points
Key Points
- The absolute risk of stroke varies 20-fold among AF patients according to age and associated vascular comorbidities. Current AHA2 guidelines use the CHADS stratification scheme.
- The major risk of antithrombotic medications used to lower the incidence of AF-related stroke is bleeding.
- For warfarin, this involves balancing a bleeding risk of 1% to 12% per year.
- The advent of several new antithrombotic agents offers alternatives to warfarin and may lower the thromboembolic risk threshold for initiating therapy in patients with AF.
Diagnosis
...Diag...
...Stroke Risk in Patients With Nonvalvular...
...ure 1. Patterns of Atrial Fibri...
Treatment
...Treatment...
Warfarin (A)...
dabigatran (B)300167
...aban (B)300167...
rivaroxaban (B)300...
...e safety and efficacy of combining dabigatran,...
...Aspirin...
...e warfarin (target INR – 2.0-3.0) is recommende...
...platelet therapy with aspirin is reco...
...patients with AF deemed unsuitable for...
...ts with ischemic stroke or TIA with p...
...ble to take oral anticoagulants, aspirin alone...
The combination of clopidogrel plus asp...
...Dabigatran...
...seful as an alternative to warfarin for the preven...
...mg twice daily is an efficacious a...
...is of pharmacokinetic data, the use of dabiga...
...e are no data to support the use of da...
...mg twice daily is an efficacious alt...
...ety and efficacy have not been established...
...5 mg twice daily is a relatively safe...
...afety and efficacy have not been establis...
...should NOT be used if the CrCI...
...Rivaroxab...
...tients with nonvalvular AF who are at m...
...with renal impairment and nonvalvular AF...
...should NOT be used if the CrCI is...
...Recommended for Stroke PreventionaAgent (Brand...
Figure 2. Prevention of Stroke in N...